Kamada - Asset Resilience Ratio
Kamada (KMDA) has an Asset Resilience Ratio of 0.00% as of June 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Kamada current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2021)
This chart shows how Kamada's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see KMDA asset base.
Liquid Assets Composition Over Time
This chart breaks down Kamada's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read KMDA liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA0.00 | 0% |
| Total Liquid Assets | ILA0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Kamada maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Kamada Industry Peers by Asset Resilience Ratio
Compare Kamada's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Shenzhen Kangtai Biological Products Co Ltd
SHE:300601 |
Drug Manufacturers - Specialty & Generic | 12.99% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
|
ChengDa Pharmaceuticals Co. Ltd.
SHE:301201 |
Drug Manufacturers - Specialty & Generic | 32.14% |
Annual Asset Resilience Ratio for Kamada (2009–2021)
The table below shows the annual Asset Resilience Ratio data for Kamada.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 0.00% | ILA0.00 ≈ $0.00 |
ILA318.67 Million ≈ $854.34K |
-- |
| 2020-12-31 | 18.55% | ILA39.07 Million ≈ $104.74K |
ILA210.66 Million ≈ $564.79K |
+0.57pp |
| 2019-12-31 | 17.98% | ILA31.25 Million ≈ $83.77K |
ILA173.80 Million ≈ $465.94K |
-5.55pp |
| 2018-12-31 | 23.53% | ILA32.50 Million ≈ $87.13K |
ILA138.12 Million ≈ $370.28K |
-1.31pp |
| 2017-12-31 | 24.84% | ILA30.34 Million ≈ $81.34K |
ILA122.11 Million ≈ $327.37K |
+6.12pp |
| 2016-12-31 | 18.72% | ILA18.66 Million ≈ $50.04K |
ILA99.70 Million ≈ $267.28K |
-4.08pp |
| 2015-12-31 | 22.80% | ILA23.26 Million ≈ $62.36K |
ILA101.99 Million ≈ $273.44K |
-8.42pp |
| 2014-12-31 | 31.22% | ILA37.35 Million ≈ $100.13K |
ILA119.62 Million ≈ $320.69K |
+20.41pp |
| 2013-12-31 | 10.81% | ILA15.07 Million ≈ $40.39K |
ILA139.38 Million ≈ $373.67K |
-8.19pp |
| 2012-12-31 | 19.00% | ILA16.93 Million ≈ $45.39K |
ILA89.11 Million ≈ $238.91K |
-0.74pp |
| 2011-12-31 | 19.74% | ILA16.87 Million ≈ $45.22K |
ILA85.45 Million ≈ $229.09K |
-2.51pp |
| 2010-12-31 | 22.25% | ILA20.36 Million ≈ $54.60K |
ILA91.52 Million ≈ $245.37K |
+21.41pp |
| 2009-12-31 | 0.84% | ILA527.72K ≈ $1.41K |
ILA62.91 Million ≈ $168.66K |
-- |
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more